{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:49:10Z","timestamp":1784177350000,"version":"3.55.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). Patients with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL) were treated with fixed-duration pirtobrutinib plus venetoclax (PV) or pirtobrutinib plus venetoclax and rituximab (PVR) in this phase 1b trial. Prior covalent BTKi therapy was allowed, but not prior treatment with venetoclax. Patients were assigned to receive PV (n = 15) or PVR (n = 10) for 25 cycles. Most patients (68%) had received prior covalent BTKi therapy. At the data cutoff date, the median time on study was 27.0 months for PV and 23.3 months for PVR. Overall response rates were 93.3% (95% confidence interval [CI], 68.1-99.8) for PV and 100% (95% CI, 69.2-100.0) for PVR, with 10 complete responses (PV: 7; PVR: 3). After 12 cycles of treatment, 85.7% (95% CI, 57.2-98.2) of PV and 90.0% (95% CI, 55.5-99.7) of PVR patients achieved undetectable minimal residual disease (&amp;lt;10-4) in peripheral blood. Progression-free survival at 18 months was 92.9% (95% CI, 59.1-99.0) for PV patients and 80.0% (95% CI, 40.9-94.6) for PVR patients. No dose-limiting toxicities were observed during the 5-week assessment period. The most common grade \u22653 adverse events (AEs) for all patients included neutropenia (52%) and anemia (16%). AEs led to dose reduction in 3 patients and discontinuation in 2. In conclusion, fixed-duration PV or PVR was well tolerated and had promising efficacy in patients with R\/R CLL, including patients previously treated with a covalent BTKi. This trial was registered at www.clinicaltrials.gov as #NCT03740529.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024024510","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T18:58:03Z","timestamp":1718132283000},"page":"1374-1386","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: the phase 1b BRUIN trial"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3806-059X","authenticated-orcid":false,"given":"Lindsey E.","family":"Roeker","sequence":"first","affiliation":[{"name":"1Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"2The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[{"name":"3Linear Clinical Research, Sir Charles Gairdner Hospital, University of Western Australia, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1071","authenticated-orcid":false,"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"6MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6836-2364","authenticated-orcid":false,"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[{"name":"7Florida Cancer Specialists, Sarah Cannon Research Institute, Sarasota, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[{"name":"8Columbia University Irving Medical Center, NewYork-Presbyterian, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"Tsai","sequence":"additional","affiliation":[{"name":"9Loxo@Lilly, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binoj","family":"Nair","sequence":"additional","affiliation":[{"name":"9Loxo@Lilly, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"10Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"9Loxo@Lilly, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[{"name":"10Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Radtke","sequence":"additional","affiliation":[{"name":"10Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Chapman","sequence":"additional","affiliation":[{"name":"10Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasimha","family":"Marella","sequence":"additional","affiliation":[{"name":"9Loxo@Lilly, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel C.","family":"McNeely","sequence":"additional","affiliation":[{"name":"9Loxo@Lilly, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"11Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2024092615202169600_bib1","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"31","key":"2024092615202169600_bib2","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024092615202169600_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/fon-2019-0844","article-title":"ALPINE: zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"16","author":"Hillmen","year":"2020","journal-title":"Future Oncol"},{"issue":"23","key":"2024092615202169600_bib4","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024092615202169600_bib5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024092615202169600_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024092615202169600_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/ejh.13973","article-title":"Sequencing and combination of current small-molecule inhibitors for chronic lymphocytic leukemia: where is the evidence?","volume":"111","author":"Chung","year":"2023","journal-title":"Eur J Haematol"},{"issue":"11","key":"2024092615202169600_bib8","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"2024092615202169600_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.2943","article-title":"Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management","volume":"40","author":"Eyre","year":"2022","journal-title":"Hematol Oncol"},{"issue":"4","key":"2024092615202169600_bib10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.hoc.2021.03.008","article-title":"Treatment of chronic lymphocytic leukemia after discontinuation of Bruton's tyrosine kinase inhibitors","volume":"35","author":"Thompson","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"2024092615202169600_bib11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11899-021-00645-1","article-title":"BTK inhibitors in chronic lymphocytic leukemia","volume":"16","author":"Gaballa","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"2024092615202169600_bib12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a\u00a0real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"2024092615202169600_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024092615202169600_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"24","key":"2024092615202169600_bib15","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024092615202169600_bib16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2023-187128","article-title":"Relapse after first-line fixed duration ibrutinib\u00a0+ venetoclax: high response rates to ibrutinib retreatment and absence of BTK mutations in patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 captivate study [abstract]","volume":"142","author":"Ghia","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2024092615202169600_bib17","doi-asserted-by":"crossref","first-page":"10803","DOI":"10.1182\/blood-2022-159648","article-title":"Understanding patient preferences for chronic lymphocytic leukemia treatments [abstract]","volume":"140","author":"Ravelo","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024092615202169600_bib18","doi-asserted-by":"crossref","first-page":"e3216","DOI":"10.1002\/hon.3216","article-title":"Patients' preferences for chronic lymphocytic leukemia treatment: the CHOICE study","volume":"42","author":"Sportoletti","year":"2024","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2024092615202169600_bib19","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1182\/blood-2023-174719","article-title":"Patient preferences for fixed versus treat-to-progression therapies in chronic lymphocytic leukemia [abstract]","volume":"142","author":"Ravelo","year":"2023","journal-title":"Blood"},{"issue":"22","key":"2024092615202169600_bib20","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024092615202169600_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2024092615202169600_bib22","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1200\/JCO.22.02283","article-title":"Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study","volume":"41","author":"Munir","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024092615202169600_bib23","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"issue":"22","key":"2024092615202169600_bib24","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2024092615202169600_bib25","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1016\/S2352-3026(22)00211-3","article-title":"Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial","volume":"9","author":"Cramer","year":"2022","journal-title":"Lancet Haematol"},{"issue":"11","key":"2024092615202169600_bib26","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/TP53mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"issue":"19","key":"2024092615202169600_bib27","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024092615202169600_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024092615202169600_bib29","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"suppl 1","key":"2024092615202169600_bib30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2022-168003","article-title":"Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease [abstract]","volume":"140","author":"Ryan","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024092615202169600_bib31","first-page":"62","article-title":"Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood J"},{"issue":"1","key":"2024092615202169600_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"2024092615202169600_bib33","doi-asserted-by":"crossref","first-page":"20406207221101697","DOI":"10.1177\/20406207221101697","article-title":"The potential of pirtobrutinib in multiple B-cell malignancies","volume":"13","author":"Jensen","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"2024092615202169600_bib34","unstructured":"US Food and Drug Administration\n          . Jaypirca (pirtobrutinib). Prescribing information. 2023. Accessed 10 October 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216059Orig1s000Corrected_lbl.pdf."},{"key":"2024092615202169600_bib35","unstructured":"FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma. 2023. Accessed 12 December 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic."},{"key":"2024092615202169600_bib36","unstructured":"US Food and Drug Administration\n          . Jaypirca (pirtobrutinib). Prescribing information. 2023. Accessed 17 January 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216059s001lbl.pdf."},{"key":"2024092615202169600_bib37","unstructured":"US Food and Drug Administration\n          . Venclexta (venetoclax). Prescribing information. 2016. Accessed 30 October 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208573s000lbl.pdf."},{"key":"2024092615202169600_bib38","unstructured":"US Food and Drug Administration\n          . Rituxan (rituximab). Prescribing information. 2012. Accessed 27 November 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103705s5367s5388lbl.pdf."},{"issue":"25","key":"2024092615202169600_bib39","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2024092615202169600_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"issue":"11","key":"2024092615202169600_bib41","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41375-021-01241-1","article-title":"Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations","volume":"35","author":"Wierda","year":"2021","journal-title":"Leukemia"},{"issue":"30","key":"2024092615202169600_bib42","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024092615202169600_bib43","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood.2020008608","article-title":"Venetoclax and ibrutinib for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"137","author":"Niemann","year":"2021","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/13\/1374\/2244100\/blood_bld-2024-024510-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/13\/1374\/2244100\/blood_bld-2024-024510-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T15:54:39Z","timestamp":1727366079000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/13\/1374\/516465\/Fixed-duration-pirtobrutinib-plus-venetoclax-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":43,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,9,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024510","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}